PBA
IMVT icon

Paradigm Biocapital Advisors’s Immunovant IMVT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,362,827
Closed -$38.9M – 34
2024
Q3 		$38.9M Hold
1,362,827
– – 1.31% 24
2024
Q2 		$36M Buy
1,362,827
+563,773
+71% +$16M 1.38% 23
2024
Q1 		$25.8M Buy
+799,054
New +$29.2M 0.91% 25

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Paradigm Biocapital Advisors's IMVT Position: Q4 2024 in Review

Paradigm Biocapital Advisors sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 1,362,827 shares — an estimated $38.9M sold.

Paradigm Biocapital Advisors first reported a position in IMVT in Q1 2024 and held it in 3 quarters. The position peaked at $38.9M in Q3 2024. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Paradigm Biocapital Advisors reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,362,827 Immunovant shares in Q4 2024, an estimated $38.9M.
  • Paradigm Biocapital Advisors first reported a position in Immunovant in Q1 2024 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Immunovant position peaked at $38.9M in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.